The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE

OMB APPROVAL
OMB Number:3235-0006
Expires:Oct 31, 2018
Estimated average burden
hours per response:23.8

COLUMN 1COLUMN 2COLUMN 3COLUMN 4COLUMN 5COLUMN 6COLUMN 7COLUMN 8
VALUESHRS ORSH/PUT/INVESTMENTOTHERVOTING AUTHORITY
NAME OF ISSUERTITLE OF CLASSCUSIP(x$1000)PRN AMTPRNCALLDISCRETIONMANAGERSOLESHAREDNONE
Adverum Biotechnologies, Inc.Common Stock00773U1086,6395,068,233SH OTR 05,068,2330
Akero Therapeutics, Inc.Common Stock00973Y1088,766617,727SH OTR 0617,7270
Aligos Therapeutics, Inc.Common Stock01626L1054,9892,320,381SH OTR 02,320,3810
Clovis Oncology, Inc.Common Stock189464100206101,855SH OTR 0101,8550
Crinetics Pharmaceuticals, Inc.Common Stock22663K1079,007410,360SH OTR 0410,3600
CRISPR Therapeutics AGCommon SharesH1718210831,294498,558SH OTR 0498,5580
CymaBay Therapeutics, Inc.Common Stock23257D1031,691543,753SH OTR 0543,7530
Gritstone Oncology, Inc.Common Stock39868T10514,6723,561,150SH OTR 03,561,1500
Minerva Surgical Inc.Common Stock60343F1067,5321,673,700SH OTR 01,673,7000
Passage Bio, Inc.Common Stock70271210015,3754,959,769SH OTR 04,959,7690